Endothelial-to-Mesenchymal Transition in Anticancer Therapy and Normal Tissue Damage

The authors review the role of hypoxia and reactive oxygen species as the main stimulating factors of tissue damage due to vascular damage and endothelial-to-mesenchymal transition (EndMT). They consider drugs that may be clinically useful for regulating EndMT in various diseases.
[Experimental and Molecular Medicine]
Full Article
Bookmark

No account yet? Register

0
Share

Vascular Extracellular Matrix Remodeling and Hypertension

Scientists summarize the dynamic changes in extracellular matrix (ECM) components and their modification and degradation during hypertension and after antihypertensive treatment. They also discuss how alterations in the ECM amount, assembly, mechanical properties, and degradation fragment generation provide input into the pathological process of hypertension.
[Antioxidants & Redox Signaling]
Full Article
Bookmark

No account yet? Register

0
Share

Emerald Health Pharmaceuticals Provides Phase II Systemic Sclerosis Clinical Trial Update

Emerald Health Pharmaceuticals, Inc. continues to advance its Phase IIa clinical study of EHP-101, an oral formulation of a patented new chemical entity derived from cannabidiol being developed for the treatment of systemic sclerosis, a severe, debilitating and life-threatening form of scleroderma, and multiple sclerosis.
[Emerald Health Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

0
Share

Adverum Biotechnologies Announces New INFINITY Phase II Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial

Adverum Biotechnologies, Inc. announced the initiation of INFINITY, a Phase II, multi-center, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal injection of ADVM-022 in patients with diabetic macular edema.
[Adverum Biotechnologies]
Press Release
Bookmark

No account yet? Register

0
Share

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase III Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. announced that the last subject completed their final visit in the company’s RESOLVE-1 Phase III trial of lenabasum for the treatment of systemic sclerosis. Topline results from the study are on track for summer 2020.
[Corbus Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

0
Share

SH3RF3 Promotes Breast Cancer Stem-Like Properties via JNK Activation and PTX3 Upregulation

Scientists identified a scaffold protein SH3RF3 that was upregulated in CSCs of breast cancer clinical tumors and cancer cell lines, and enhanced the CSC properties of breast cancer cells.
[Nature Communications]
Ostrander, E. L., Kramer, A. C., Mallaney, C., Celik, H., Koh, W. K., Fairchild, J., Haussler, E., Zhang, C. R. C., & Challen, G. A. (2020). Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness. Stem Cell Reports, 0(0). https://doi.org/10.1016/j.stemcr.2020.02.011 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Director of US Agency Key to Vaccine Development Leaves Role Suddenly Amid Coronavirus Pandemic

Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization.
[STAT News]
Bookmark

No account yet? Register

0
Share

Euscaphic Acid and Tormentic Acid Protect Vascular Endothelial Cells against Hypoxia-Induced Apoptosis via PI3K/AKT or ERK 1/2 Signaling Pathway

Euscaphic acid protected vascular endothelial cells against hypoxia-induced apoptosis via ERK1/2 signaling pathway, and tormentic acid brought its efficacy into full play via PI3K/AKT and ERK1/2 signaling pathways.
[Life Sciences]
Bookmark

No account yet? Register

0
Share

Sirtuins Family as a Target in Endothelial Cell Dysfunction: Implications for Vascular Aging

The authors summarize how sirtuin 1 and other sirtuins may contribute to endothelial cell function and how presence of diseased conditions may alter their expressions to cause endothelial dysfunction.
[Biogerontology ]
Bookmark

No account yet? Register

0
Share

LncRNA SNHG1 Regulates Vascular Endothelial Cell Proliferation and Angiogenesis via miR-196a

The authors found SNHG1 was upregulated in TNF-α-treated HUVECs. They silenced SNHG1 and found it inhibited vascular endothelial cell proliferation and angiogenesis.
[Journal of Molecular Histology]
Bookmark

No account yet? Register

+1
Share

Chi-Med Announces Surufatinib Granted US FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announced that the FDA has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors (NET) and extra-pancreatic NET in patients who are not amenable for surgery.
[Hutchison China MediTech Limited]
Abstract
Bookmark

No account yet? Register

+2
Share
Share